For patients with advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel treatment is associated ...

MUSC research to use he immune system to fight cancer shows it can be done safer, cheaper and better. An SC company pushing ...

Nivolumab plus ipilimumab did not improve OS vs chemotherapy in patients with previously untreated, unresectable/metastatic urothelial carcinoma.

Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for ...

Results from a new study help resolve the decade-long mystery of why many patients with the deadliest form of skin cancer do ...

Artificial intelligence (AI) technologies and machine learning (ML) algorithms are witnessing tremendous growth in immunology ...

A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug dostarlimab with ...

Endometrial cancer (EC) is a prevalent uterine cancer that remains a major contributor to cancer-associated morbidity and mortality. EC diagnosed at advanced stages shows a poor therapeutic response.

Some 10 million people in the U.S. have oral premalignant disease, a group of diseases that show up as red patches, white ...